Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 127


Determinants of specialist physician ambulatory visits: a neurology example.

van der Goes DN, Ney JP, Garrison LP.

J Med Econ. 2019 May 13:1. doi: 10.1080/13696998.2019.1618861. [Epub ahead of print]


Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.

Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr.

J Med Econ. 2019 May 3:1-8. doi: 10.1080/13696998.2019.1614933. [Epub ahead of print]


Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.

Garrison LP Jr, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA.

Value Health. 2019 Apr;22(4):408-415. doi: 10.1016/j.jval.2018.11.014. Epub 2019 Mar 11.


Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.

Garrison LP, Jackson T, Paul D, Kenston M.

J Manag Care Spec Pharm. 2019 Feb 20:1-7. doi: 10.18553/jmcp.2019.18378. [Epub ahead of print]


The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, Garrison L Jr, Donnell D.

Value Health. 2019 Feb;22(2):194-202. doi: 10.1016/j.jval.2018.09.001. Epub 2018 Nov 2.


Value-Based Pricing in Latin America: How Far Away Are We?

Mejía A, Gilardino R, Kristensen FB, Garrison LP; ISPOR Health Technology Assessment Latin America Roundtable.

Value Health Reg Issues. 2018 Dec;17:219-223. doi: 10.1016/j.vhri.2018.09.007. Epub 2018 Dec 6.


Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.

Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL.

Value Health. 2018 Oct;21(10):1133-1149. doi: 10.1016/j.jval.2018.08.005. Review. Erratum in: Value Health. 2019 Mar;22(3):383. Value Health. 2019 Apr;22(4):502.


Cost-Effectiveness of Strategies for the Diagnosis and Treatment of Febrile Illness in Children.

Babigumira JB, Gelband H, Garrison LP Jr..

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 15.


Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis.

Zimmermann M, Vodicka E, Holman AJ, Garrison LP Jr.

J Med Econ. 2018 Jul;21(7):712-720. doi: 10.1080/13696998.2018.1470519. Epub 2018 May 11.


Insurance coverage for genomic tests.

Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP Jr, Douglas MP, Weldon CB.

Science. 2018 Apr 20;360(6386):278-279. doi: 10.1126/science.aas9268. Epub 2018 Apr 19. No abstract available.


Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.

de Montigny S, Adamson BJS, Mâsse BR, Garrison LP Jr, Kublin JG, Gilbert PB, Dimitrov DT.

Sci Rep. 2018 Apr 17;8(1):6066. doi: 10.1038/s41598-018-24268-4.


A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Garrison LP Jr, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC.

Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.


Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].

Willke RJ, Neumann PJ, Garrison LP Jr, Ramsey SD.

Value Health. 2018 Feb;21(2):155-160. doi: 10.1016/j.jval.2017.12.011.


Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].

Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM.

Value Health. 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007.


An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].

Garrison LP Jr, Pauly MV, Willke RJ, Neumann PJ.

Value Health. 2018 Feb;21(2):124-130. doi: 10.1016/j.jval.2017.12.006.


A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].

Neumann PJ, Willke RJ, Garrison LP Jr.

Value Health. 2018 Feb;21(2):119-123. doi: 10.1016/j.jval.2017.12.012.


Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation.

Devine EB, Perfetto E, Pickard AS, Schumock GT, Segal JB, Cannon E, Gagnon JP, Brixner DI, Garrison LP, Murray MD.

J Comp Eff Res. 2018 Feb;7(2):167-175. doi: 10.2217/cer-2017-0059. Epub 2018 Feb 21.


Prevalence of and Comorbid Health Conditions Associated With Pediatric Prescription Opioid Use in the US.

Banerjee S, Roland CL, Willke R, Mardekian J, Garrison LP Jr.

J Pain Palliat Care Pharmacother. 2017 Sep - Dec;31(3-4):218-227. doi: 10.1080/15360288.2017.1407860. Epub 2017 Dec 20.


Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.

Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL.

J Opioid Manag. 2017 Sep/Oct;13(5):291-301. doi: 10.5055/jom.2017.0398.


Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda.

Li M, Nyabigambo A, Navvuga P, Nuwamanya E, Nuwasiima A, Kaganda P, Asiimwe FT, Vodicka E, Mugisha NM, Mukose A, Kwesiga DK, Lubinga SJ, Garrison LP Jr, Babigumira JB.

Papillomavirus Res. 2017 Dec;4:17-21. doi: 10.1016/j.pvr.2017.06.004. Epub 2017 Jun 8.

Supplemental Content

Loading ...
Support Center